Merrimack Pharmaceuticals One Kendal Square Suite B7201

Cambridge, MA, United States

Merrimack Pharmaceuticals One Kendal Square Suite B7201

Cambridge, MA, United States
SEARCH FILTERS
Time filter
Source Type

Fitzgerald J.B.,Merrimack Pharmaceuticals One Kendal Square Suite B7201 | Johnson B.W.,Merrimack Pharmaceuticals One Kendal Square Suite B7201 | Baum J.,Merrimack Pharmaceuticals One Kendal Square Suite B7201 | Adams S.,Merrimack Pharmaceuticals One Kendal Square Suite B7201 | And 13 more authors.
Molecular Cancer Therapeutics | Year: 2014

Although inhibition of the insulin-like growth factor (IGF) signaling pathway was expected to eliminate a key resistance mechanism for EGF receptor (EGFR)-driven cancers the effectiveness of IGF-I receptor (IGF-IR) inhibitors in clinical trials has been limited. Amultiplicity of survival mechanisms are available to cancer cells. Both IGF-IR and the ErbB3 receptor activate the PI3K/AKT/mTOR axis but ErbB3 has only recently been pursued as a therapeutic target. We show that coactivation of the ErbB3 pathway is prevalent in a majority of cell lines responsive to IGF ligands and antagonizes IGF-IR-mediated growth inhibition. Blockade of the redundant IGF-IR and ErbB3 survival pathways and downstream resistance mechanisms was achieved with MM-141 a tetravalent bispecific antibody antagonist of IGF-IR and ErbB3. MM-141 potency was superior to monospecific and combination antibody therapies and was insensitive to variation in the ratio of IGF-IR and ErbB3 receptors. MM-141 enhanced the biologic impact of receptor inhibition in vivo as a monotherapy and in combination with the mTOR inhibitor everolimus, gemcitabine, or docetaxel through blockade of IGF-IR and ErbB3 signaling and prevention of PI3K/AKT/mTOR network adaptation. Mol Cancer Ther; 13(2); 410-25 © 2014 American Association for Cancer Research.

Loading Merrimack Pharmaceuticals One Kendal Square Suite B7201 collaborators
Loading Merrimack Pharmaceuticals One Kendal Square Suite B7201 collaborators